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(57) ABSTRACT 
A method and kit for immobilization of a glycoprotein. The 
method may include activating an affinity Support. The affin 
ity Support may be activated by reacting the affinity Support 
with a compound that is reactive with one or more functional 
groups included within the glycoprotein. The method may 
also include oxidizing the glycoprotein in which oxidation 
conditions are selected to yield an oxidized glycoprotein that 
is biologically active and contains a Sufficient number of 
reactive aldehyde groups for coupling to a Support. For 
example, the oxidized glycoprotein may include five reactive 
aldehyde groups. In addition, the method may include react 
ing the oxidized-glycoprotein with the activated affinity Sup 
port to immobilize the glycoprotein. 
13 Claims, 4 Drawing Sheets 
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1. 
MMOBILIZATION METHOD FOR 
PRODUCING ACTIVE o-ACID 
GLYCOPROTEIN 
CROSS REFERENCE TO RELATED 5 
APPLICATIONS 
The present application claims the benefit under 35 U.S.C. 
S 119(e) of U.S. Provisional Patent Application Ser. No. 
60/672,941, entitled “Immobilization Method for Producing 10 
Active Alpha 1-Acid Glycoprotein filed Apr. 19, 2005 
which is herein incorporated by reference in its entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH ORDEVELOPMENT 15 
This invention was made with government Support under 
GM044931 awarded by the National Institute of Health. The 
government has certain rights in the invention. 
2O 
FIELD OF THE INVENTION 
The present invention relates generally to the field of pro 
tein immobilization, and particularly to an immobilization 
method for producing active C.-acid glycoprotein. 25 
BACKGROUND OF THE INVENTION 
The binding of serum proteins with drugs has long been of 
interest since it affects the transportation and distribution of 30 
pharmaceutical agents in the body. One serum protein that is 
often involved in this process is O-acid glycoprotein (AGP). 
This protein has a carbohydrate content of 45% (w/w). The 
mean molecular mass for its native form is approximately 
41,000 g/mol. AGP has a single polypeptide chain with up to 35 
five carbohydrate moieties. It has been estimated that there 
are 12-20 differentforms of AGP in serum due to variations in 
its amino acid sequence and the types and numbers of carbo 
hydrate groups attached to its polypeptide chain. 
Although the exact biological function of AGP is still not 40 
clear, the binding of drugs to AGP has long been of interest 
since this may affect the transport and distribution of such 
agents in the body. This binding occurs primarily with basic 
and neutral Solutes and is thought to mainly involve hydro 
phobic interactions; however, coulombic interactions, hydro- 45 
gen bonding and steric effects may also be present. 
Various techniques have been previously used to examine 
the binding of drugs to AGP. Examples include equilibrium 
dialysis, ultrafiltration, capillary electrophoresis and various 
spectroscopic methods. Recent reports with AGP or other 50 
serum proteins like human serum albumin (HSA) have also 
explored the use of high performance affinity chromatogra 
phy (HPAC) and surface plasmon resonance biosensors for 
studying the binding of these proteins with drugs. Advantages 
of these later techniques versus traditional Solution-phase 55 
methods include their improved precision, their ease of auto 
mation, the convenience with which they can provide equi 
librium and kinetic information on drug-protein binding, and 
their ability to reuse the same protein preparation for hun 
dreds of samples. 60 
One desirable feature in the immobilization of a protein for 
binding studies is to have the protein in a final form that 
closely mimics the behavior of its native form. It has been 
demonstrated in many studies based on HPAC that immobi 
lized HSA closely mimics the binding of drugs to the soluble 65 
form of this protein. However, previous studies with immo 
bilized AGP have been successful. For instance, reports in 
2 
which AGP has been immobilized through ionic immobiliza 
tion and cross-linking have produced materials with a poor 
correlation versus the behavior of soluble AGP. In addition, 
no successful reports using currently available commercial 
AGP columns for drug-protein binding studies have yet been 
reported, despite the widespread use of Such columns for 
chiral separations. 
Therefore, it would be desirable to provide a method of 
AGP immobilization which produces immobilized AGP 
which closely mimics the behavior of AGP in its native form. 
SUMMARY OF THE INVENTION 
Accordingly, the present invention provides a method for 
the immobilization of AGP based on the mild oxidation of 
AGP to generate aldehyde groups in its carbohydrate regions. 
This oxidized form of AGP will then be reacted with a 
hydrazide-activated support. The behavior of immobilized 
AGP that is produced by this method is evaluated by using it 
in HPLC columns to examine the binding to R- and S-pro 
pranolol, two solutes that have relatively well-characterized 
interactions with soluble AGP. The binding of the resulting 
immobilized AGP to other drugs is also determined. 
In a first aspect of the present invention, a method for 
immobilization of a glycoprotein. In an embodiment, the 
method may include activating an affinity Support. The affin 
ity Support may be activated by reacting the affinity Support 
with a compound that is reactive with one or more functional 
groups included with the glycoprotein. The method may also 
include oxidizing the glycoprotein in which oxidation condi 
tions are selected to yield an oxidized glycoprotein that is 
biologically active and includes a sufficient number of reac 
tive aldehyde groups for coupling to a Support. For example, 
the oxidized glycoprotein may include five reactive aldehyde 
groups. In addition, the method may include reacting the 
oxidized-glycoprotein with the activated affinity Support to 
immobilize the glycoprotein. 
In accordance with a further aspect of the present inven 
tion, a glycoprotein immobilization kit is provided. In Such 
aspect, the kit may include an affinity Support for immobiliz 
ing the glycoprotein. Further, an activating solution for acti 
Vating the affinity Support so that the Support is reactive with 
one or more functional groups within the glycoprotein may be 
included. For instance, the activating Solution may include a 
hyrazide-containing agent. In addition, the kit may include an 
oxidizing solution for oxidizing the glycoprotein. In an 
aspect, the oxidizing solution is of a composition that yields 
an oxidized glycoprotein that is biologically active and con 
tains a sufficient number of reactive aldehyde groups (e.g., at 
least five reactive aldehyde groups) for coupling to a Support. 
Reacting the oxidized-glycoprotein to the activated affinity 
Support. 
In accordance with an additional aspect of the present 
invention, a solid Support for use in a chiral separation assay 
is provided. The Solid Support may have an hydrazide-acti 
vated surface which is reactive with one or more functional 
groups of an oxidized alpha one (C.) acid glycoprotein. For 
instance, the oxidized-glycoprotein may include at least five 
reactive aldehyde groups. The oxidized glycoprotein may be 
reacted with the hydrazide-activated support surface to 
immobilize the glycoprotein by linking the oxidized-glyco 
protein to the hydrazide-activated Support. Such reaction 
forms a hydrazide-linked alpha one (C) acid glycoprotein 
complex capable of separating a chiral drug. 
It is to be understood that both the foregoing general 
description and the following detailed description are exem 
plary and explanatory only and are not restrictive of the inven 
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tion as claimed. The accompanying drawings, which are 
incorporated in and constitute a part of the specification, 
illustrate an embodiment of the invention and together with 
the general description, serve to explain the principles of the 
invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The numerous advantages of the present invention may be 
better understood by those skilled in the art by reference to the 
accompanying figures in which: 
FIG. 1 is a flow chart illustration of a method of immobi 
lization of a glycoprotein in accordance with an exemplary 
embodiment of the present invention; 
FIG. 2A is a schematic illustration of the oxidation of 
O-acid glycoprotein by periodate acid in accordance with an 
exemplary embodiment of the present invention; 
FIG. 2B is a schematic illustration of the preparation of 
hydrazide-activated silica in accordance with an exemplary 
embodiment of the present invention; 
FIG. 2C is a schematic illustration of the immobilization of 
C-acid glycoprotein to a hydrazide-activated Support in 
accordance with an exemplary embodiment of the present 
invention; 
FIG.3A is a schematic illustration of the degree of C.-acid 
glycoprotein oxidation at various periodate concentrations in 
accordance with an exemplary embodiment of the present 
invention, wherein the ratio of Lucifer yellow per C.-acid 
glycoprotein (LyCH/AGP) is a measure of the number of 
aldehyde groups that are available for coupling on C.-acid 
glycoprotein; 
FIG.3B is a schematic illustration of the degree of C.-acid 
glycoprotein immobilized to hydrazide-actiated silica after 
oxidation at various periodate concentrations in accordance 
with an exemplary embodiment of the present invention; and 
FIG. 4 is a schematic illustration of the rate of immobili 
zation for oxidized O-acid glycoprotein in accordance with 
an exemplary embodiment of the present invention, wherein 
oxidized C.-acid glycoprotein was oxidized with 20 mM 
periodate for 10 minutes at room temperature before immo 
bilization. 
DETAILED DESCRIPTION OF THE INVENTION 
Reference will now be made in detail to the presently 
preferred embodiments of the invention, examples of which 
are illustrated in the accompanying drawings. 
Referring to FIG. 1, a method 100 for immobilization of a 
glycoprotein is provided. In an exemplary embodiment, the 
method 100 may include activating an affinity support 102. In 
such embodiment, the affinity support may be activated by 
reacting the affinity Support with a compound that is reactive 
with one or more functional groups included within the gly 
coprotein. For instance, for alpha one (C) acid glycoprotein 
the affinity Support may be activated with hydrazide, amine, 
and other like related agents. In addition, the activated silica 
Support may be employed to immobilize a glycoprotein Such 
as O-acid glycoprotein. 
In further embodiments, the method 100 may include oxi 
dizing the glycoprotein 104. In an exemplary embodiment, 
oxidation conditions are selected to maximize the activity of 
the glycoprotein after oxidation. For example, in order to 
maximize the activity of C.-acid glycoprotein, conditions 
were chosen Such that excessive damage to the carbohydrate 
chains oramino acids within C-acid glycoprotein's structure 
did not occur. Further, the oxidation conditions were chosen 
so that a sufficient number of aldehyde groups (e.g., at least 
10 
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five) were present to couple C-acid glycoprotein to an acti 
vated Support. In an embodiment, oxidation conditions may 
include reacting the glycoprotein such as C.-acid glycopro 
tein with the oxidizing reagent periodate or by using compa 
rable oxidative procedures. It is contemplated that periodate 
concentrations may range from 0.01 mM to 50 mM, and 
preferably from 5 mM to 20 mM. 
The method 100 may also include reacting the oxidized 
glycoprotein with the activated affinity support 106 to immo 
bilize the glycoprotein by linking the oxidized-glycoprotein 
to the activated affinity support. In addition, the immobilized 
glycoprotein may be washed 108 following reacting the oxi 
dized glycoprotein with the activated affinity support to 
remove remaining non-reacted compound. Moreover, the 
method 100 may include employing the immobilized glyco 
protein for separating chiral drugs 110 Such as propranolol 
and other like related compounds. 
In accordance with a further embodiment of the present 
invention, a glycoprotein immobilization kit is provided. In 
an exemplary embodiment, the kit may include an affinity 
Support for immobilizing the glycoprotein. Further, an acti 
Vating solution for activating the affinity Support so that the 
Support is reactive with one or more functional groups within 
the glycoprotein may be included. For instance, the activating 
Solution includes a reagent such as hydrazide, amine, and 
other like compounds. 
In further exemplary embodiments, the kit may include an 
oxidizing solution for oxidizing the glycoprotein. In an 
embodiment, the oxidizing Solution is of a composition that 
yields an oxidized glycoprotein that is biologically active and 
contains a sufficient number of reactive aldehyde groups 
(e.g., at least five reactive aldehyde groups) for coupling to a 
Support. For example, the oxidizing solution may include 
oxidation conditions may include the oxidizing reagent perio 
date. It is contemplated that periodate concentrations may 
range from 0.01 mM to 50 mM, and preferably from 5 mM to 
20 mM. In an alternative embodiment, the oxidizing solution 
includes approximately 20 mM sodium acetate and approxi 
mately 0.15 mM sodium chloride in a one to one volume to 
Volume ratio with periodate concentrations ranging from 5 
mM to 20 mM. The kit may also include a washing solution 
for washing the activated affinity Support following reacting 
the oxidized glycoprotein with the activated affinity support 
to remove remaining non-reacted compound on the affinity 
Support. For example, the washing solution may include 
In an additional exemplary embodiment, a solid Support for 
use in a chiral separation assay is disclosed. In an embodi 
ment, the Solid Support may have an activated Surface includ 
ing hydrazide or amine groups, or other like activated Sur 
faces. In the embodiment, the hydrazide-activated surface 
may be reactive with one or more functional groups of an 
oxidized glycoprotein such as C.-acid glycoprotein. For 
instance, this may be obtained through the use of approxi 
mately five aldehyde groups in active O-acid glycoprotein, 
Such as is produced by oxidizing O-acid glycoprotein with 5 
to 20 mM periodate for 10 minutes at pH 7.0 and 4° C. 
Reacting the oxidized glycoprotein with the activated Support 
Surface immobilizes the glycoprotein by linking the oxidized 
glycoprotein to the activated Support. As such, a hydrazide 
linked glycoprotein complex capable of separating a chiral 
drug (e.g., propanolol and like compounds) is formed. 
Some of the specific examples in accordance with exem 
plary embodiments of the present invention are provided 
below. Further, additional examples in accordance with the 
present invention may be found in the publication entitled 
“Immobilization of C-acid glycoprotein for chromato 
graphic Studies of drug-protein binding. Analytical Bio 
US 7,575,908 B1 
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chemistry, Volume 346, 2005, pages 300 to 310 by Hai Xuan 
and David S. Hage, which is herein incorporated by reference 
in its entirety. 
EXAMPLE1 
Preparation of Oxidized C-acid Glycoprotein 
FIG. 2A illustrates an exemplary method for preparing 
oxidized C.-acid glycoprotein. The conditions chosen for this 
reaction vary according to the final degree of oxidation 
desired. For instance, 2 to 5 milligram (mg)/milliliter (mL) 
O-acid glycoprotein was dissolved in pH 7.0, 20 mM sodium 
acetate and 0.15 M sodium chloride and combined in a 1:1 
(v/v) ratio with 5-20 mM periodic acid in the same buffer. In 
Such example, C-acid glycoprotein had a purity of at least 
99.0% and was prepared from a pooled serum sample that 
included approximately 44% of the F variant of AGP, 29% of 
the S variant and 27% of the A variant. This mixture was 
allowed to react for 10 to 15 minutes at room temperature in 
the dark and quenched by adding 0.25 mL ethylene glycol per 
milliliter of sample. After this new mixture had reacted for 2 
minutes, it was put into a dialysis bag at 4°C. for 2 hours 
against 2 liters pH 7.0, 20 mMacetate buffer containing 0.15 
M sodium chloride. This was followed by three additional 
two-hour dialysis cycles against 2 liter portions of pH 7.0, 
0.10 M potassium phosphate buffer. 
EXAMPLE 2 
Analysis of Oxidized C.-acid Glycoprotein 
The extent of O-acid glycoprotein oxidation produced by 
following the procedures described in Example 1 was moni 
tored using Luciferyellow (LyCH) as a labeling agent. In this 
technique, a 3 mg/mL solution of LyCH in pH 6.5, 0.10 M 
phosphate buffer was mixed with an equal portion of an 
oxidized C-acid glycoprotein solution prepared in Example 
1 and allowed to react for 2 hours. This mixture was then 
applied to a 10 mL Econo-Pac 10DG column (Bio-Rad Labo 
ratories) to remove the excess LyCH using pH 7.0, 0.10 M 
phosphate buffer as the mobile phase. The labeled AGP was 
then collected and dialyzed for several hours at 4°C. against 
two to three 2 L portions of pH 7.4, 0.10 Mphosphate buffer. 
The amount of LyCH per C-acid glycoprotein in the 
labeled sample was determined by using a manual absor 
bance method. To do this, calibration curves were first con 
structed at 280 nm for 0-2 mg/mL. C.-acid glycoprotein and at 
both 280 and 428 nm for 0-3 mg/mL LyCH in pH 7.4, 0.10 M 
phosphate buffer (Note: C.-acid glycoprotein has no measur 
able absorbance at 428 nm). These curves gave linear rela 
tionships with a molar absorptivity of 2.91 (+0.02)x10" M' 
cm for O-acid glycoprotein at 280 nm and molar absorp 
tivities for LyCH of 2.62 (+0.08)x10" M' cm at 280 nm 
and 1.27 (+0.05)x10'M' cm at 428 nm. 
For the analysis of LyCH-labeled C.-acid glycoprotein, the 
LyCH concentration in each sample was determined by using 
the sample's absorbance at 428 nm. The measured LyCH 
concentration was then used along with the known molar 
absorptivity of LyCH at 280 nm to calculate the absorbance 
for LyCH at 280 nm in the labeled sample. This absorbance 
was then subtracted from the total absorbance measured for 
the sample at this wavelength and used to determine the 
concentration of C.-acid glycoprotein. These results were 
combined to give the LyCH/C-acid glycoprotein ratio for the 
sample, which provided a measure of number of aldehydes 
available on the oxidized C-acid glycoprotein for coupling to 
hydrazide groups. 
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EXAMPLE 3 
Immobilization of Oxidized C.-acid Glycoprotein 
First, hydrazide-activated silica was prepared as shown in 
FIG.2B. For example, 1 g of Nucleosil Si-300 obtained from 
Alltech (Deerfield, Ill.) was placed in 8.5 mL of pH 5.5, 0.1 M 
Sodium acetate buffer and degassed by Sonication under 
vacuum for 10 to 15 minutes. Next, 0.20 mL of 3-glycidox 
ypropyltrimethoxysilane was added and the solution was 
shaken for 5 hours at 90° C. The epoxy silica formed by this 
reaction was washed several times with water and a pH 3.0 
Sulfuric acid solution. This Support was next Suspended in a 
pH 3.0 sulfuric acid solution (using 100 mL of this solution 
per gram of silica) and refluxed for 90 minutes. The diol 
bonded silica formed as the product was washed with several 
portions of water, methanol, and ether and dried overnight 
under vacuum at room temperature. To make dihydrazide 
activated silica, 1 g of the diol-bonded silica was suspended in 
20 mL of a 90% (v/v) acetic acid-water mixture containing 1 
g periodic acid. This mixture was Sonicated under reduced 
pressure for 10 to 15 minutes and shaken for 2 hours at room 
temperature. The resulting aldehyde silica was washed four 
times with deionized water or pH 7.0, 0.1 M phosphate buffer 
to remove any excess periodic acid. To this aldehyde silica 
was then added 50 mL of pH 7.0, 0.1 M phosphate buffer 
containing 0.13 g oxalic dihydrazide. This mixture was 
shaken for 1 to 2 hours, centrifuged and washed four times 
with pH 7.0, 0.1 M phosphate buffer. After activation, the 
remaining aldehyde groups were reduced by adding 0.2 g 
sodium borohydride in 20 mL of pH 8.0, 0.1 M phosphate 
buffer. This mixture was shaken for 90 minutes and washed 
four times with water. The hydrazide silica was stored under 
vacuum at room temperature or in the pH 7.0 phosphate 
buffer at 4° C. 
Oxidized C-acid glycoprotein was immobilized to 
hydrazide-activated silica by a procedure illustrated in FIG. 
2C. In exemplary studies, a 5 mL portion of pH 7.0, 0.10 M 
phosphate buffer containing 1.5 mg/mL oxidized C-acid 
glycoprotein was mixed with 0.03 grams of hydrazide-acti 
vated silica. This mixture was Sonicated under aspirator 
vacuum for 10 minutes to remove any air bubbles from the 
Suspension. It was then placed onto a shaker and allowed to 
react at 4°C. for up to seven days, with more than two days 
being optimum. The reaction was stopped by centrifuging the 
reaction mixture and removing the Supernatant. The Support 
was next washed several times with pH 7.0, 0.10 Mphosphate 
buffer, followed by several additional washings with deion 
ized water. Any hydrazide groups remaining on this Support 
were removed by adding a 200-fold excess of glyceraldehyde 
Versus the Supports original hydrazide content. This mixture 
was shaken at 4°C. for 6 hours. The support was thenwashed 
several times with pH 7.0, 0.10 M phosphate buffer. The 
amount of immobilized C-acid glycoprotein was determined 
by comparing the final and initial concentrations of C-acid 
glycoprotein in the reaction slurry, using absorbance mea 
surements at 280 nm. 
EXAMPLE 4 
Chromatographic Studies with R- and S-Propranolol 
The O-acid glycoprotein and hydrazide-activated Sup 
ports were downward slurry-packed at 28 MPa (4000 psi) into 
US 7,575,908 B1 
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50x4.1 mm I.D. stainless steel columns. These columns were 
enclosed in water jackets for temperature control. All Studies, 
except those examining the temperature dependence of pro 
pranolol—C.-acid glycoprotein binding, were performed at 
37°C. The mobile phases and packing solutions were pre- 5 
pared using pH 7.4 phosphate buffered saline (PBS, compo 
sition: 0.013 M potassium dihydrogen phosphate, 0.053 M 
disodium hydrogen phosphate and 0.133 Msodium chloride). 
Prior to use, all mobile phases were filtered through a 0.45um 
cellulose acetate filter and degassed under vacuum for 10 min. 
Elution of R- and S-propranolol was detected by monitoring 
the absorbance at 225 nm. Zonal elution studies were per 
formed on the C-acid glycoprotein column by applying pH 
7.4 phosphate buffer solution containing up to 20 uM of the is 
desired competing agent while making 20 uIl injections of 
R-propranolol or S-propranolol onto the column. At each 
concentration of competing agent, three replicate injections 
of the desired analyte were made. The propranolol samples 
were prepared by dissolving 5.0 LM R- or S-propranolol in 
the appropriate mobile phase. All mobile phases containing 
propranolol were prepared using the individual enantiomers 
or propranolol. The flow rate ranged from 0.8 to 1.5 mL/min, 
with no significant changes in the retention factors being 
10 
Analyte 
S-Propranolol 
R-Propranolol 
noted under this range of conditions. There was also no 35 
observed change in retention with Small variations in the 
amount of injected propranolol, indicating that linear elution 
conditions were present during these experiments. 
The retention times for propranolol were calculated using 
a B/As method. The column void volume was determined by 
making injections of sodium nitrate onto a column containing 
only hydrazide-activated silica while monitoring the absor 
bance at 205 nm. All elution times were corrected for the 
extra-column Volume of the chromatographic system, as 
determined by making injections of R-propranolol or S-pro 
pranolol when no column was present. A correction for the 
Small amount of non-specific binding between propranolol 
and the hydrazide Support was made by measuring the reten 
tion factors for this drug on a column equivalent in size to the 
C-acid glycoprotein column, but containing only hydrazide 
activated silica. This was measured at each propranolol con 
centration in the mobile phase and accounted for 3-15% of the 
retention factors noted for propranolol on the C-acid glyco 
protein column. The C-acid glycoprotein columns were 
found to be stable over at least three months, with only a 5% 
change in retention being noted over the course of 50 injec 
tions and the application of 4000 column volumes of the 
mobile phase. The column was stored in pH 7.4 PBS buffer at 
4°C. when not in use. 
40 
45 
50 
55 
60 
The effects of oxidation on C-acid glycoprotein are pre 
sented in Table 1, below. All of the results presented in Table 
1 were determined at 37° C. in pH 7.4 phosphate buffered 
saline. The numbers in parentheses represent a range of it one 
standard deviation. 
65 
Periodate conc. used for AGP oxidation 
Measured property 10 mM 20 nM 50 mM 
AGP immobilized 10.2 (+0.2) 15.8 (+0.4) 14.5 (+0.5) 
(mg/g silica) 
Binding capacity (mgg silica) 6.8 (-0.2) 6.3 (+0.3) 6.8 (+0.3) 
Specific activity 
(mg/mg AGP) 
Association constant 
(x10M) 
0.67 (+0.02) 0.40 (+0.02) 0.47 (+0.03) 
3.1 (+0.2) 3.0 (+0.3) 0.95 (+0.05) 
The effect of temperature on the binding of R- and S-pro 
pranolol to C-acid glycoprotein columns is presented in 
Table 2, below. All of the results presented in Table 2 were 
generated by performing self-competition Zonal elution stud 
ies at temperatures ranging from 5° C. to 37° C. in pH 7.4 
phosphate buffered saline. The numbers in parentheses rep 
resent a range of it one standard deviation. 
Association equilibrium constant, K. (M- 
37o C. 25o C. 15° C. 5oC. 
4.2 (+0.3) x 10° 5.2 (+1.7) x 10 9 (+2) x 10° 11 (+3) x 10 
2.7 (+0.2) x 10° 3.9 (+0.2) x 10° 7 (+1) x 10° 8 (+2) x 10° 
The effect of other separation conditions such as pH were 
also evaluated. For instance, as the pH decreased from 7.4 to 
4.8, the retention factor for R-propranolol decreased from 
132 to 17.8 (87%), while the retention factor for S-propra 
nolol decreased from 167 to 17.8 (89%). This pH dependent 
behavior indicates that the immobilized O-acid glycoprotein 
is mimicking the behavior of Such protein in Solution. 
EXAMPLE 5 
Drug Screening on O-acid Glycoprotein Column 
The binding of other drugs to the O.-acid glycoprotein 
columns were examined at 25 or 37°C. using pH 7.4, 0.067M 
potassium phosphate buffer. These drugs were selected based 
on their binding to soluble O-acid glycoprotein. Samples of 
each drug were prepared at a concentration of 5 mM. The 
injection volume for each sample was 25 LIL, with all samples 
being examined in triplicate. The detection wavelengths were 
as follows: imipramine, 210 nm; pindolol, 216 nm, trifluop 
erazine, 257 mm; and epinephrine and isoproterenol. 203 nm. 
All other drugs were monitored at 225 nm. All samples were 
used within one day of preparation. The present conditions 
yielded a more effective approach for the immobilization of 
C-acid glycoprotein with perphenZaine, triflupromazine, 
quinidine, and lidocaine when compared to previously 
reported findings. Further, the presently employed immobi 
lization method gave better performance than thiol-based 
immobilization in work with O-acid glycoprotein and other 
compounds (e.g., pindolol, quinidine, and propranolol). 
Referring to FIG. 3A, the degree of C.-acid glycoprotein 
oxidation at various periodate concentrations in accordance 
with Example 3 of the present invention is provided. In the 
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present Example, reactions occurred over a 10 minute time 
period at 4°C. in pH 7.0 buffer including 20 mM sodium 
acetate and 0.15M sodium chloride. As illustrated in FIG.3A, 
an increase in the amount of Lucifer yellow (LyCH) per 
C-acid glycoprotein (LyCH/AGP) occurred as the concen 
tration of periodate increased from 0 mM and 0.5 mM. Fur 
ther, a plateau in the LyCH/AGP ratio was observed between 
10 mM and 50 mM. The LyCH/AGP ratio observed under 
these conditions indicates that there were up to five usable 
aldehyde groups generated per O-acid glycoprotein mol 
ecule. It is contemplated that the aldehyde groups are located 
in the terminal sialic acid regions with the glycoprotein's 
carbohydrate chain since Such regions are known to be the 
most Susceptible of periodate oxidation under the presently 
employed conditions. 
Referring to FIG.3B, the degree of C.-acid immobilized to 
hydrazide-actiated silica after oxidation at various periodate 
concentrations in accordance with Example 3 of the present 
invention is illustrated. As illustrated in FIG. 3B, at 0.05 mM 
periodate there was no significant amount of O-acid glyco 
protein immobilized even though it was known that Such 
conditions gave about one reactive aldehyde group per 
C-acid glycoprotein. However, an increase in the amount of 
immobilized C.-acid glycoprotein was observed with an 
increase in periodate concentration, particularly in the range 
of 0.05 mM to 5 mM periodate. This value reached 13.8 
milligrams of C-acid glycoprotein per gram silica when 5 
mM periodate was used, with similar values being observed 
for periodate concentrations up to 50 mM. As illustrated in 
FIG. 3A, this is the same range of conditions that gave rise to 
five reactive aldehydes per O-acid glycoprotein. 
It is contemplated that C.-acid glycoprotein containing 
fewer than five aldehyde groups was unable to be immobi 
lized effectively to the hydrazide-activated support due to 
steric hindrance, where many of these aldehydes groups may 
not have been able to come in contact with the supports 
Surface. Thus, based upon the present experimental findings, 
a preferred embodiment involves oxidizing O-acid glyco 
protein by reacting 5-20 mM periodate (typically 10 mM for 
optimum reproducibility) for 10 min at 4°C. with 5.0 mg/mL 
O-acid glycoprotein in a pH 7.0 buffer containing 20 mM 
sodium acetate and 0.15 M sodium chloride. 
Referring to FIG. 4, rate of immobilization for oxidized 
C-acid glycoprotein in accordance with an exemplary 
embodiment of the present invention in which oxidized 
C.-acid glycoprotein was oxidized with 20 mM periodate for 
10 minutes at room temperature before immobilization. As 
illustrated in FIG. 4, approximately two-thirds of the maxi 
mum amount of immobilized C-acid glycoprotein was 
obtained within 24 hours, with over ninety percent of maxi 
mum coverage being achieved within approximately two 
days. Further, longer coupling times did not result in signifi 
cant change. Under Such conditions, thirty-three percent of 
the added C-acid glycoprotein was immobilized in 24 hours 
with half remaining in solution after the immobilization had 
reached completion. Therefore, the present conditions 
appeared to be adequate to Saturate the available coupling 
sites on the Support. 
It is believed that the present invention and many of its 
attendant advantages will be understood by the foregoing 
description. It is also believed that it will be apparent that 
various changes may be made in the form, construction and 
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arrangement of the components thereof without departing 
from the scope and spirit of the invention or without sacrific 
ing all of its material advantages. The form herein before 
described being merely an explanatory embodiment thereof. 
Further, it is to be understood that the claims included below 
are merely exemplary of the present invention and are not 
intended to limit the scope of coverage which has been 
enabled by the written description. 
What is claimed is: 
1. A method for immobilization of an alpha one (C) acid 
glycoprotein, comprising: 
activating an affinity Support, the affinity Support being 
activated by reacting the affinity Support with a com 
pound that is reactive with one or more functional 
groups including within the one (C) acid glycoprotein; 
oxidizing the alpha one (C.) acid glycoprotein, oxidation 
conditions being selected to i) yield an oxidized alpha 
one (C) acid glycoprotein that includes at least five 
reactive aldehyde groups and ii) maximize activity of 
said alpha one (C.) acid glycoprotein after oxidation, 
wherein said oxidation conditions comprise reacting the 
alpha one (C.) acid glycoprotein with 5 mM to 20 mM 
periodate for about 10 to 15 minutes; 
reacting the oxidized alpha one (C.) acid glycoprotein with 
the activated affinity support to immobilize the alpha one 
(C.) acid glycoprotein by linking the oxidized alpha one 
(C.) acid glycoprotein to the activated affinity Support. 
2. The method as claimed in claim 1, wherein the oxidized 
alpha one (C) acid glycoprotein includes five reactive alde 
hyde groups. 
3. The method as claimed in claim 1, wherein the activated 
affinity support is a hydrazide-activated support. 
4. The method as claimed in claim 1, wherein the activated 
affinity Support is an amine-activated Support. 
5. The method as claimed in claim 1, further comprising 
washing the immobilized alpha one (C) acid glycoprotein 
following reacting the oxidized alpha one (C) acid glycopro 
tein with the activated affinity Support to remove remaining 
non-reacting alpha one (C) acid glycoprotein. 
6. The method as claimed in claim 1, wherein oxidation 
conditions include reacting the alpha one (C) acid glycopro 
tein with 5 mM to 20 mM periodate at room temperature. 
7. The method as claimed in claim 1, wherein the oxidation 
conditions include reacting the alpha one (C) acid glycopro 
tein with 5 mM to 20 mM periodate at about 4°C. 
8. The method as claimed in claim 1, wherein the activated 
affinity Support is a hydrazide-activated silica Support. 
9. The method as claimed in claim 1, further comprising 
employing the immobilized alpha one (C.) acid glycoprotein 
for separating chiral drugs. 
10. The method as claimed in claim 9, wherein chiral drugs 
include propranolol. 
11. The method of claim 1, wherein said oxidation condi 
tions comprise reacting said alpha one (C.) acid glycoprotein 
at a concentration of about 2 to 5 milligram/milliliter. 
12. The method of claim 1, wherein said oxidation condi 
tions comprise reacting said alpha one (C) acid glycoprotein 
at about pH 7.0. 
13. The method of claim 1, wherein said oxidation condi 
tions comprise reacting said alpha one (C) acid glycoprotein 
at about pH 7.0 for about 10 minutes at about 4°C. 
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